104 related articles for article (PubMed ID: 3323994)
21. [Place of carbohydrate antigens in the spectrum of protein tumor markers in patients with tumors at different sites].
Reznikov IuP; Ul'ianov VI; Variukhin AS; Vanin AI; Vorontsova LP
Vopr Onkol; 1988; 34(1):51-6. PubMed ID: 3422524
[TBL] [Abstract][Full Text] [Related]
22. CA125 measurement in epithelial ovarian cancer: a 10-year anniversary of clinical investigation.
Berkowitz RS
Gynecol Oncol; 1993 Apr; 49(1):1-2. PubMed ID: 8482551
[No Abstract] [Full Text] [Related]
23. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
24. Ovarian tumor antigens.
Benson MD; Lurain JR; Newton M
J Reprod Med; 1983 Jan; 28(1):17-23. PubMed ID: 6187917
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.
Vergote IB; Børmer OP; Abeler VM
Am J Obstet Gynecol; 1987 Jul; 157(1):88-92. PubMed ID: 2440307
[TBL] [Abstract][Full Text] [Related]
26. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
[TBL] [Abstract][Full Text] [Related]
27. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
28. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
29. CA125 as a serum marker for poor prognosis in ovarian malignancies.
Alvarez RD; To A; Boots LR; Shingleton HM; Hatch KD; Hubbard J; Soong SJ; Potter ME
Gynecol Oncol; 1987 Mar; 26(3):284-9. PubMed ID: 2435619
[TBL] [Abstract][Full Text] [Related]
30. Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report.
Dembo AJ; Chang PL; Urbach GI
Obstet Gynecol; 1985 May; 65(5):710-4. PubMed ID: 3856794
[TBL] [Abstract][Full Text] [Related]
31. Monitoring CA 125 serum levels during early chemotherapy is an excellent prognostic method in advanced ovarian cancer.
Högberg T; Kågedal B
Gynecol Oncol; 1993 Mar; 48(3):413-4. PubMed ID: 8462909
[No Abstract] [Full Text] [Related]
32. [Serum levels of the CA-125 antigen in the diagnosis of ovarian neoplasms].
Sopracordevole F; Finco B; Scarabelli C; Campagnutta E; Alimena C; Perin A
Minerva Ginecol; 1985 Oct; 37(10):589-96. PubMed ID: 3866146
[No Abstract] [Full Text] [Related]
33. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
34. [Simultaneous determination of Ca 125 and D-dimer in plasma and ascites in ovarian cancer].
Schröck R; Hafter R; Graeff H; Schmid L
Onkologie; 1985 Oct; 8(5):260-2. PubMed ID: 2999668
[TBL] [Abstract][Full Text] [Related]
35. [A clinical evaluation of CA 125 levels in serum, ascites and pleural effusion].
Jibiki K; Demura R; Abe Y; Odagiri E; Demura H
Gan No Rinsho; 1987 Nov; 33(14):1756-62. PubMed ID: 3480363
[TBL] [Abstract][Full Text] [Related]
36. Management of early ovarian cancer.
Young RC; Pecorelli S
Semin Oncol; 1998 Jun; 25(3):335-9. PubMed ID: 9633845
[TBL] [Abstract][Full Text] [Related]
37. The treatment of early stage ovarian cancer.
Young RC
Semin Oncol; 1995 Oct; 22(5 Suppl 12):76-9. PubMed ID: 7481865
[TBL] [Abstract][Full Text] [Related]
38. Ovarian tumour antigens as potential targets for immune gene therapy.
Kuiper M; Peakman M; Farzaneh F
Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
[TBL] [Abstract][Full Text] [Related]
39. [Possibilities and limitations of the clinical use of specific monoclonal antibodies for epithelial ovarian carcinomas: CA125K].
Pozzi V; D'Onofrio T; Cappa F; Mascaretti G; Meggiorini ML; Nusiner MP; Danese M
Minerva Ginecol; 1985 May; 37(5):253-7. PubMed ID: 3861960
[No Abstract] [Full Text] [Related]
40. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
